PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up [Yahoo! Finance]
Puma Biotechnology Inc (PBYI)
Last puma biotechnology inc earnings: 2/20 04:07 pm
Check Earnings Report
US:NYSE Investor Relations:
pumabiotechnology.com/ir.html
Company Research
Source: Yahoo! Finance
In the year-ago quarter, the company had reported adjusted earnings of 17 cents per share. The above-adjusted earnings exclude the impact of stock-based compensation expense. Including the same, the reported earnings per share were 41 cents in the third quarter of 2024 compared with earnings of 12 cents reported in the year-ago quarter. In the third quarter, total revenues were $80.5 million, which also beat the Zacks Consensus Estimate of $71 million. Revenues increased around 43.5% year over year. Total revenues comprised net product sales of Nerlynx (neratinib), PBYI's only marketed drug in the United States, and royalty revenues. Nerlynx is indicated for treating early-stage HER2-positive breast cancer. Shares of Puma Biotechnology were up 12.2% in after-hours trading on Nov. 7 owing to the better-than-expected results and the sales performance of Nerlynx. The stock has plunged 30% so far this year compared with the industry's 2.4% decrease. Image Source: Zacks Investmen
Show less
Read more
Impact Snapshot
Event Time:
PBYI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBYI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBYI alerts
High impacting Puma Biotechnology Inc news events
Weekly update
A roundup of the hottest topics
PBYI
News
- Puma Biotechnology, Inc. (NASDAQ: PBYI) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Should Value Investors Buy Puma Biotechnology (PBYI) Stock? [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology, Inc. (NASDAQ: PBYI) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer [Yahoo! Finance]Yahoo! Finance
PBYI
Earnings
- 11/7/24 - Beat
PBYI
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- PBYI's page on the SEC website